NEWS
- Pharma & Biotech News #PharmaBuzz
- Weekly News Recap #Phispers
- Recent Product Approvals #GreenLight
- Quality Compliance Alerts #Warning!
- All News #Library
DRUGS & DEVELOPMENTS
MARKET INTEL by PharmaCompass
Create content with us, ask us
By PharmaCompass
2019-03-28
Impressions: 100 Article
In the US, insulin makers Eli Lilly, Sanofi and Novo Nordisk have been in the eye of a storm since 2017, battling pricing lawsuits, and more recently a class action suit that accuses the players of fraudulently inflating the prices of insulin.
Due to the increased scrutiny, Eli Lilly released data that indicates the amount the company received for its popular insulin injection — Humalog — which declined 8.1 percent over the past five years. The net price for Humalog — which factors in the rebates and other incentives Lilly provides to customers — fell to US$ 135 in 2018 from US$ 147 in 2014.
While the net price has declined, the list price has risen 52 percent to US$ 594. The last time the company raised the list price for Humalog was in 2017, it said. Lilly’s list prices for Humalog and what most patients are charged after insurance company rebates and other discounts highlights the disparity in prices between uninsured and insured patients.
Lilly cited increased negotiating power of pharmaceutical benefit managers (PBMs) as one of the reasons for the decline, warning that “changes in insurance design and the trend toward greater consumer cost sharing” could mean more patients are forced to pay the full retail price.
The PharmaCompass Newsletter – Sign Up, Stay Ahead
Feedback, help us to improve. Click here
Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0
“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”
